GLP-1s tied to lowest fracture risk among diabetes drugs: Study

A study found that GLP-1 drugs are associated with a lower risk of fractures, including hip and osteoporotic fractures. 

The research, led by scientists from China and published in Acta Diabetologica, analyzed more than 490,000 adverse event reports from the FDA’s Adverse Event Reporting System between 2004 and 2022. Of the reports, 99,000 involved GLP-1 receptor agonists. 

The study found that compared to other diabetes medications, GLP-1 receptor agonists had the lowest reporting odds ratio of any fracture-related adverse events, at 0.44. 

The trend surfaced across fracture types, including osteoporotic and hip fractures. Among individual GLP-1 receptor agonist drugs, albiglutide showed the most pronounced reduction in fracture risk, researchers said. 

The post GLP-1s tied to lowest fracture risk among diabetes drugs: Study appeared first on Becker’s Hospital Review | Healthcare News & Analysis.